In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

GlaxoSmithKline avoided rebate obligations tied to the Flovent price inflation, the lawsuit says. "It raised the price so much that, with the removal of the rebate cap, GSK was faced with the ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent” ...

GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

Something seems to be going awry with GlaxoSmithKline's game plan for its ... over £1.09 billion and down 19 per cent in the US. GSK chief executive Andrew Witty told investors yesterday that ...

Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...

GlaxoSmithKline has agreed a $3.3 billion takeover ... that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts ...